BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7368100)

  • 1. Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary report.
    Hubay CA; Pearson OH; Marshall JS; Rhodes RS; Debanne SM; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
    Surgery; 1980 May; 87(5):494-501. PubMed ID: 7368100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
    Hubay CA; Gordon NH; Crowe JP; Guyton SP; Pearson OH; Marshall JS; Mansour EG; Hermann RE; Jones JC; Flynn WJ
    Surgery; 1984 Jul; 96(1):61-72. PubMed ID: 6740497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result.
    Hubay CA; Pearson OH; Manni A; Gordon NH; McGuire WL
    J Steroid Biochem; 1985 Dec; 23(6B):1147-50. PubMed ID: 3912620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.
    Pearson OH; Hubay CA; Marshall JS; Gordon NH; McGuire WL; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C
    Breast Cancer Res Treat; 1983; 3 Suppl():S61-8. PubMed ID: 6367862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence patterns in a prospective study of patients with stage II breast cancer treated with endocrine-chemotherapy.
    Crowe JP; Gordon NH; Antunez AR; Hubay CA; Pearson OH; Marshall JS; McGuire WL
    Surgery; 1987 Oct; 102(4):622-7. PubMed ID: 3310297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial.
    Hubay CA; Pearson OH; Marshall JS; Rhodes RS; DeBanne SM; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
    Cancer; 1980 Dec; 46(12 Suppl):2805-8. PubMed ID: 7004624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
    Hartman AR; Fleming GF; Dillon JJ
    Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.
    Bezwoda WR; Derman D; De Moor NG; Lange M; Levin J
    Cancer; 1982 Dec; 50(12):2747-50. PubMed ID: 6754067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
    Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up.
    Marshall JS; Gordon NH; Hubay CA; Pearson OH
    J Lab Clin Med; 1987 Mar; 109(3):300-7. PubMed ID: 3819572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term tamoxifen plus chemotherapy: superior results in node-positive breast cancer.
    Crowe JP; Gordon NH; Shenk RR; Soegiarso RW; Hubay CA; Mansour EG; Shuck JM; Pearson OH; Marshall JS; Arafah B
    Surgery; 1990 Oct; 108(4):619-27; discussion 627-8. PubMed ID: 2218871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer.
    Hubay CA; Pearson OH; Marshall JS; Rhodes RS; Debanne SM; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
    Eur J Cancer (1965); 1980; Suppl 1():189-95. PubMed ID: 7032932
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy for metastatic breast cancer.
    Haskell CM; Sparks FC; Graze PR; Korenman SG
    Ann Intern Med; 1977 Jan; 86(1):68-80. PubMed ID: 835932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
    Mouridsen HT; Palshof T; Engelsman E; Sylvester R
    Eur J Cancer (1965); 1980; Suppl 1():119-23. PubMed ID: 7032921
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
    Jiang Z; Song S; Liu X
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.